Fenebrutinib:Results of a Phase II, Randomized, Double
Results of a Phase II, Randomized, Double
![Results of a Phase II, Randomized, Double](https://i0.wp.com/api.multiavatar.com/Results+of+a+Phase+II%2C+Randomized%2C+Double-Blind%2C+Placebo+....png?apikey=viVnb6N20jclO8)
由DIsenberg著作·2021·被引用63次—Objective:Fenebrutinib(GDC-0853)isanoncovalent,oral,andhighlyselectiveinhibitorofBruton'styrosinekinase(BTK).Theefficacy,safety,and ...。其他文章還包含有:「Genentech:PressReleases|Tuesday」、「Fenebrutinib」、「Fenebrutinib」、「FenebrutinibinH1antihistamine」、「Fenebrutinib(GDC-0853)」、「InvestigationofFenebrutinibMetabolismandBioactivation...」、「臨床試驗...
查看更多 離開網站![Genentech: Press Releases | Tuesday](https://i0.wp.com/api.multiavatar.com/Genentech%3A+Press+Releases+%7C+Tuesday%2C+May+16%2C+2023.png?apikey=viVnb6N20jclO8)
Genentech: Press Releases | Tuesday
https://www.gene.com
Fenebrutinib is an investigational oral, reversible and non-covalent BTK inhibitor that blocks the function of BTK. BTK, also known as tyrosine- ...
![Fenebrutinib](https://i0.wp.com/api.multiavatar.com/Fenebrutinib+%7C+C37H44N8O4+%7C+CID+86567195.png?apikey=viVnb6N20jclO8)
Fenebrutinib
https://pubchem.ncbi.nlm.nih.g
Fenebrutinib is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib ...
![Fenebrutinib](https://i0.wp.com/api.multiavatar.com/Fenebrutinib.png?apikey=viVnb6N20jclO8)
Fenebrutinib
https://www.mssociety.org.uk
Fenebrutinib is a new drug being investigated for the treatment of relapsing and primary progressive MS. Phase 2 and 3 trials are currently recruiting ...
![Fenebrutinib in H1 antihistamine](https://i0.wp.com/api.multiavatar.com/Fenebrutinib+in+H1+antihistamine-refractory+chronic+....png?apikey=viVnb6N20jclO8)
Fenebrutinib in H1 antihistamine
https://pubmed.ncbi.nlm.nih.go
Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb ...
![Fenebrutinib (GDC-0853)](https://i0.wp.com/api.multiavatar.com/Fenebrutinib+%28GDC-0853%29+%7C+Btk+Inhibitor+%7C+MedChemExpress.png?apikey=viVnb6N20jclO8)
Fenebrutinib (GDC-0853)
https://www.medchemexpress.com
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, ...
![Investigation of Fenebrutinib Metabolism and Bioactivation ...](https://i0.wp.com/api.multiavatar.com/Investigation+of+Fenebrutinib+Metabolism+and+Bioactivation+....png?apikey=viVnb6N20jclO8)
Investigation of Fenebrutinib Metabolism and Bioactivation ...
https://pubmed.ncbi.nlm.nih.go
Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the ...
![臨床試驗結果摘要](https://i0.wp.com/api.multiavatar.com/%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E7%B5%90%E6%9E%9C%E6%91%98%E8%A6%81.png?apikey=viVnb6N20jclO8)
臨床試驗結果摘要
https://forpatients.roche.com
fenebrutinib 或安慰劑(一種看起來像fenebrutinib 但不含藥物的藥丸)。 • 本試驗在11 國納入160 位患者。 • 主要的發現,是fenebrutinib 的安全性足以由本試驗的患者耐受 ...